Ignite Creation Date:
2025-12-25 @ 12:26 AM
Ignite Modification Date:
2025-12-25 @ 10:32 PM
Study NCT ID:
NCT01185158
Status:
COMPLETED
Last Update Posted:
2023-11-29
First Post:
2010-08-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006258', 'term': 'Head and Neck Neoplasms'}, {'id': 'D007818', 'term': 'Laryngeal Diseases'}, {'id': 'C562489', 'term': 'Lymphoid Interstitial Pneumonia'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D010038', 'term': 'Otorhinolaryngologic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077156', 'term': 'Gefitinib'}], 'ancestors': [{'id': 'D011799', 'term': 'Quinazolines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 46}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2002-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-11', 'completionDateStruct': {'date': '2010-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-27', 'studyFirstSubmitDate': '2010-08-17', 'studyFirstSubmitQcDate': '2010-08-18', 'lastUpdatePostDateStruct': {'date': '2023-11-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2010-08-19', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2004-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'To assess the activity of 250mg of ZD1839 administered as a single agent to patients with recurrent or metastatic or both recurrent and metastatic head and neck cancer.', 'timeFrame': '2 -5 years'}], 'secondaryOutcomes': [{'measure': 'To demonstrate the effectiveness of ZD 1839 as an inhibitor of epithelial growth factor (EGFR) phosphorylation, MAP kinase activation, and vascular endothelial growth (VEGF) secretion in metastatic head and neck cancer.', 'timeFrame': '2-5 years'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Larynx', 'Lip', 'Oral Cavity and Pharynx'], 'conditions': ['Head and Neck Cancer']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://uccrc.uchicago.edu', 'label': 'The University of Chicago Comprehensive Cancer Center Web page'}]}, 'descriptionModule': {'briefSummary': "The purpose of this study is to find out what effects (good and bad) ZD1839 has on one's squamous cell head and neck cancer. The research is being done because currently no effective treatment exists for metastatic (spread of cancer cells from one area of the body to another) or recurrent squamous cell cancer of the head and neck. The purpose of this study is to find out if ZD1839 can shrink tumors or cause tumors to stop growing for a period of time."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Histologically confirmed squamous cell carcinoma of the head and neck incurable by surgery or radiation\n* Patients must have measurable disease, defined as at least on e lesion that can be accurately measured in the one dimension (longer diameter to be recorded) as greater then or equal to 20mm with conventional techniques or as greater than or equal to 10mm with computed tomograpy (CT) scan.\n\nTherapeutic history that includes the Following:\n\n* No prior EGFR-based therapy for recurrent disease\n* No chemotherapy or irradiation with the 28-day period preceding entry to the study\n* Eastern Cooperative Oncology Group (ECOG)performance Status 0-2 (kamofsky \\>59%)\n\nPatients must have normal organ and marrow function as defined below:\n\n* leukocytes \\>3,000ml\n* absolute neutrophil count 1,500/ml\n* platelets 100,000/ml\n* total bilirubin within normal institutional limits\n* AST(SGOT)ALT(SGPT) \\<2.5 X institutional upper limits of normal\n* Creatinine \\<1.5\n\nExclusion Criteria:\n\n* Other coexisting malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical in situ.\n* Concomitant use of phenytoin, carbamazepine, barbiturates, rifampicin, phenobarbital, ketoconazole, erythromycin, clarithromycin, atorvastatin, cimetidine, ametidine, amitriptyline, imipramine, verpamil, tamoxifen, chlorpromazine, amiodorone, chloroquine, St. John's Wort\n* Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy\n* Incomplete healing from previous oncologic or other major surgery Patients may not be receiving any other investigational agents\n* History of allergic reactions attributed to compound of similar chemical or biologic composition to ZD 1839\n* Uncontrolled intercurrent illness\n* Pregnancy or breast feeding (women of child -bearing potential"}, 'identificationModule': {'nctId': 'NCT01185158', 'briefTitle': 'A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma', 'organization': {'class': 'OTHER', 'fullName': 'University of Chicago'}, 'officialTitle': 'A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma', 'orgStudyIdInfo': {'id': '11588A'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ZD1839 (IRESSA) 250mg', 'description': 'ZD1839(IRESSA) 250mg orally (po) daily', 'interventionNames': ['Drug: ZD1839 (IRESSA)']}], 'interventions': [{'name': 'ZD1839 (IRESSA)', 'type': 'DRUG', 'description': 'ZD1839: 250mg/day po or via g-tube Q 24 hours', 'armGroupLabels': ['ZD1839 (IRESSA) 250mg']}]}, 'contactsLocationsModule': {'locations': [{'zip': '60653', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'The University of Chicago Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}], 'overallOfficials': [{'name': 'Ezra Cohen, M.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The Univesity of Chicago Medical Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Chicago', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}